Economic evaluation of Qili Qiangxin capsules for the treatment of chronic heart failure

Read full text Summarise with VIRAT
Authors: Hualiang Deng, Sijun Yu, Fan WANG, Chun-hui Liu, Xia Liu, Xiao-ye Wang, Wen-ling Xu, Jia-xin Wang, Guanzhong Zheng, Jian-hua Zhou, Xing-ze Xie, Yong He
+9 more Kai-yan Zhang, Di-fei Gao, Jia-yu Cui, Guifang Sun, Decai Li, Xing-hong Xie, Iokfai Cheang, Ningxin Ding, Zhen-hua Jia
Cited by: 0
References: 21

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction Chronic heart failure (CHF) confers high mortality and heavy economic burden as a critical public health issue. Qili Qiangxin (QLQX) capsules, a traditional Chinese patent medicine, may improve clinical outcomes in CHF patients. This study evaluated the economic value of QLQX capsules for CHF. Methods A health economic analysis was performed from the healthcare system perspective. Cost-effectiveness analysis was used for short-term outcomes, and a Markov model-based cost-utility analysis for long-term outcomes. Robustness was tested using one-way and probabilistic sensitivity analyses. Results A total of 1555 patients were equally randomized to two groups: QLQX capsules plus standard of care (QLQX group) or standard of care alone (control group). Baseline characteristics were comparable between groups. In the QLQX group, 1-year direct medical costs were ¥9368.08 ($1311.53; 95% confidence interval [CI]: [¥8980.61, ¥9755.55]), versus ¥6402.21 ($896.31; 95% CI: [¥5903.50, ¥6900.91]) in the control group. The higher costs in the QLQX group were primarily driven by medication expenses. Composite endpoint events occurred in 19.00% (95% CI: [17.07%, 21.03%]) of the QLQX group compared with 23.40% (95% CI: [21.34%, 25.61%]) of the control group (P = 0.003). The incremental cost-effectiveness ratio (ICER) was ¥67 406.14 ($9436.86). Over a 15-year time horizon, the QLQX group incurred total costs of ¥57 096 ($7993.44) and achieved 5.46 QALYs, whereas the control group incurred ¥34 016 ($4762.24) and achieved 5.07 QALYs, resulting in an ICER of ¥58 946 per QALY ($8252.44/QALY). This value is below China’s 2023 per capita gross domestic product threshold (¥89 358; $12 510.12), suggesting that QLQX capsule is highly cost-effective. Sensitivity analyses further confirmed the robustness of these findings. Conclusion QLQX capsules were associated with higher short-term costs but greater efficacy than standard care, and long-term modeling supports their high cost-effectiveness.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Heart Failure Treatment and Management Pharmaceutical Economics and Policy

Publication details

Journal / source
Evidence-Based Chinese Medicine and Technology Assessment
Volume
2
Issue
1
Pages
9570029–9570029
Publication date
1 March 2026
Language
EN